Mufemilast vs Roflumilast (Zoryve)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriasis

Shared mechanism: PDE4 · full Psoriasis pipeline

Mufemilast

Marketed by Tianjin Hemay Pharmaceutical

Phase 3 in Psoriasissmall molecule
Partial signal

NCT04839328 · Phase 3 · completed

The study randomized 306 participants to Hemay005 or placebo, with participants masked to treatment, and used the clinical PASI75 response as its primary endpoint. Because no comparative results or statistical analysis are posted, the primary endpoint cannot be assessed.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Reported efficacy

Proportion of subjects who have 75% or more reduction in [Psoriasis area-and-severity index score (PASI)] (PASI75). (week 16): PASI75 比例分别为 53.6% vs 16.0%,sPGA 0/1 率分别为 31.3% vs 6.4% (PASI75 at week 16: Hemay005 53.6% vs placebo 16.0%; sPGA 0/1: 31.3% vs 6.4%) (met)

Result source: NCT04839328

Roflumilast (Zoryve)

Marketed by Arcutis Biotherapeutics and partners

Approved in Psoriasissmall molecule
Partial signal

NCT06648772 · Phase 3 · completed

The study randomly assigned 190 participants to roflumilast cream or vehicle cream and used quadruple blinding of participants, care providers, investigators, and outcome assessors. Its primary endpoint was a clinical psoriasis severity measure, but whether that endpoint was met cannot be determined because results are not available.

Next expected readout: July 2027 · NCT07725822 (registry estimate)

Reported efficacy

Number of Participants Achieving Success on the Investigator Global Assessment (IGA) Scale (Week 8): Number of Participants Achieving Success on the Investigator Global Assessment (IGA) Scale (Week 8): Roflumilast Cream 0.3% 99/264 (37.5%) vs Vehicle Cream 9/131 (6.9%) (met)

Result source: NCT04211389

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointMufemilastRoflumilast (Zoryve)
PASI 75—Not posted · NCT0483932841.6% vs 7.6%+34 vs placebo0.3% cream · wk 8 · n 255NCT04211363
9 other results
  • 39% vs 5.3% 0.3% cream · wk 8 · n 264 · Phase 3 · secondary NCT04211389
  • 34.1% vs 16% 0.3% · wk 12 · n 109 · Phase 2 · secondary NCT03638258
  • 31.1% vs 16% 0.15% · wk 12 · n 113 · Phase 2 · secondary NCT03638258
  • 31.3% vs 13.2% 0.3% · wk 8 · n 109 · Phase 2 · secondary NCT03638258
  • 23% vs 13.2% 0.15% · wk 8 · n 113 · Phase 2 · secondary NCT03638258
  • 24.1% vs 9.6% 0.3% · wk 6 · n 109 · Phase 2 · secondary NCT03638258
  • 22.2% vs 9.6% 0.15% · wk 6 · n 113 · Phase 2 · secondary NCT03638258
  • 13.3% vs 10.5% 0.3% · wk 4 · n 109 · Phase 2 · secondary NCT03638258
  • 7.6% vs 10.5% 0.15% · wk 4 · n 113 · Phase 2 · secondary NCT03638258
PASI 90—Not posted · NCT0483932822.4% vs 2.3%+20.1 vs placebo0.3% cream · wk 8 · n 255NCT04211363
9 other results
  • 15.5% vs 2% 0.3% cream · wk 8 · n 290 · Phase 3 · secondary NCT04211389
  • 20.6% vs 7.8% 0.3% · wk 12 · n 109 · Phase 2 · secondary NCT03638258
  • 13.7% vs 7.8% 0.15% · wk 12 · n 113 · Phase 2 · secondary NCT03638258
  • 16.9% vs 6% 0.3% · wk 8 · n 109 · Phase 2 · secondary NCT03638258
  • 7.4% vs 6% 0.15% · wk 8 · n 113 · Phase 2 · secondary NCT03638258
  • 14.3% vs 3.2% 0.3% · wk 6 · n 109 · Phase 2 · secondary NCT03638258
  • 2.3% vs 3.2% 0.15% · wk 6 · n 113 · Phase 2 · secondary NCT03638258
  • 6% vs 2.3% 0.3% · wk 4 · n 109 · Phase 2 · secondary NCT03638258
  • 1.3% vs 2.3% 0.15% · wk 4 · n 113 · Phase 2 · secondary NCT03638258
PASI 100—Not posted · NCT04839328—Not posted · NCT06648772
sPGA 0/1—Not posted · NCT04839328—Not posted · NCT06648772
DLQI, change—Not posted · NCT04839328-2.6 vs -1.4−1.2 vs placebo0.3% · wk 12 · n 58NCT03638258
7 other results
  • -4.2 vs -1.4 0.15% · wk 12 · n 60 · Phase 2 · secondary NCT03638258
  • -2.6 vs -1.6 0.3% · wk 8 · n 58 · Phase 2 · secondary NCT03638258
  • -3.5 vs -1.6 0.15% · wk 8 · n 60 · Phase 2 · secondary NCT03638258
  • -2.6 vs -1.8 0.3% · wk 6 · n 58 · Phase 2 · secondary NCT03638258
  • -3.1 vs -1.8 0.15% · wk 6 · n 60 · Phase 2 · secondary NCT03638258
  • -2.2 vs -1.9 0.3% · wk 4 · n 58 · Phase 2 · secondary NCT03638258
  • -2.3 vs -1.9 0.15% · wk 4 · n 60 · Phase 2 · secondary NCT03638258

PASI 75

Mufemilast
—Not posted · NCT04839328
Roflumilast (Zoryve)
41.6% vs 7.6%+34 vs placebo0.3% cream · wk 8 · n 255NCT04211363
9 other results
  • 39% vs 5.3% 0.3% cream · wk 8 · n 264 · Phase 3 · secondary NCT04211389
  • 34.1% vs 16% 0.3% · wk 12 · n 109 · Phase 2 · secondary NCT03638258
  • 31.1% vs 16% 0.15% · wk 12 · n 113 · Phase 2 · secondary NCT03638258
  • 31.3% vs 13.2% 0.3% · wk 8 · n 109 · Phase 2 · secondary NCT03638258
  • 23% vs 13.2% 0.15% · wk 8 · n 113 · Phase 2 · secondary NCT03638258
  • 24.1% vs 9.6% 0.3% · wk 6 · n 109 · Phase 2 · secondary NCT03638258
  • 22.2% vs 9.6% 0.15% · wk 6 · n 113 · Phase 2 · secondary NCT03638258
  • 13.3% vs 10.5% 0.3% · wk 4 · n 109 · Phase 2 · secondary NCT03638258
  • 7.6% vs 10.5% 0.15% · wk 4 · n 113 · Phase 2 · secondary NCT03638258

PASI 90

Mufemilast
—Not posted · NCT04839328
Roflumilast (Zoryve)
22.4% vs 2.3%+20.1 vs placebo0.3% cream · wk 8 · n 255NCT04211363
9 other results
  • 15.5% vs 2% 0.3% cream · wk 8 · n 290 · Phase 3 · secondary NCT04211389
  • 20.6% vs 7.8% 0.3% · wk 12 · n 109 · Phase 2 · secondary NCT03638258
  • 13.7% vs 7.8% 0.15% · wk 12 · n 113 · Phase 2 · secondary NCT03638258
  • 16.9% vs 6% 0.3% · wk 8 · n 109 · Phase 2 · secondary NCT03638258
  • 7.4% vs 6% 0.15% · wk 8 · n 113 · Phase 2 · secondary NCT03638258
  • 14.3% vs 3.2% 0.3% · wk 6 · n 109 · Phase 2 · secondary NCT03638258
  • 2.3% vs 3.2% 0.15% · wk 6 · n 113 · Phase 2 · secondary NCT03638258
  • 6% vs 2.3% 0.3% · wk 4 · n 109 · Phase 2 · secondary NCT03638258
  • 1.3% vs 2.3% 0.15% · wk 4 · n 113 · Phase 2 · secondary NCT03638258

PASI 100

Mufemilast
—Not posted · NCT04839328
Roflumilast (Zoryve)
—Not posted · NCT06648772

sPGA 0/1

Mufemilast
—Not posted · NCT04839328
Roflumilast (Zoryve)
—Not posted · NCT06648772

DLQI, change

Mufemilast
—Not posted · NCT04839328
Roflumilast (Zoryve)
-2.6 vs -1.4−1.2 vs placebo0.3% · wk 12 · n 58NCT03638258
7 other results
  • -4.2 vs -1.4 0.15% · wk 12 · n 60 · Phase 2 · secondary NCT03638258
  • -2.6 vs -1.6 0.3% · wk 8 · n 58 · Phase 2 · secondary NCT03638258
  • -3.5 vs -1.6 0.15% · wk 8 · n 60 · Phase 2 · secondary NCT03638258
  • -2.6 vs -1.8 0.3% · wk 6 · n 58 · Phase 2 · secondary NCT03638258
  • -3.1 vs -1.8 0.15% · wk 6 · n 60 · Phase 2 · secondary NCT03638258
  • -2.2 vs -1.9 0.3% · wk 4 · n 58 · Phase 2 · secondary NCT03638258
  • -2.3 vs -1.9 0.15% · wk 4 · n 60 · Phase 2 · secondary NCT03638258
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Mufemilast
PASI75 比例分别为 53.6% vs 16.0%,sPGA 0/1 率分别为 31.3% vs 6.4% (PASI75 at week 16: Hemay005 53.6% vs placebo 16.0%; sPGA 0/1: 31.3% vs 6.4%) NCT04839328 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Mufemilast: 0 of 4 rows · Roflumilast (Zoryve): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricRoflumilast (Zoryve)
Dropout rate
10.8%0.3% creama
NCT04211363 · Phase 3
show 10 more results
9%0.3% cream
NCT04211389 · Phase 3
0%0.3% daily
NCT04746911 · Phase 2 · registry result, not featured evidence
0%0.3% cream
NCT04655313 · Phase 2 · registry result, not featured evidence
28.7%Cohort 1: Study 201 Participants
NCT03764475 · Phase 2 · registry result, not featured evidence
21.6%Cohort 2: Non-study 201 Participan
NCT03764475 · Phase 2 · registry result, not featured evidence
8%0.15%
NCT03638258 · Phase 2 · registry result, not featured evidence
—0.3%
NCT03638258 · Phase 2 · registry result, not featured evidence
0%0.5%
NCT03392168 · Phase 1/2 · registry result, not featured evidence
—0.15%
NCT03392168 · Phase 1/2 · registry result, not featured evidence
—0.5%
NCT03392168 · Phase 1/2 · registry result, not featured evidence
Discontinued due to AEs
1.7%0.3% creama
NCT04211363 · Phase 3
show 10 more results
0.3%0.3% cream
NCT04211389 · Phase 3
—0.3% daily
NCT04746911 · Phase 2 · registry result, not featured evidence
—0.3% cream
NCT04655313 · Phase 2 · registry result, not featured evidence
4.8%Cohort 1: Study 201 Participants
NCT03764475 · Phase 2 · registry result, not featured evidence
2%Cohort 2: Non-study 201 Participan
NCT03764475 · Phase 2 · registry result, not featured evidence
0%0.15%
NCT03638258 · Phase 2 · registry result, not featured evidence
—0.3%
NCT03638258 · Phase 2 · registry result, not featured evidence
—0.5%
NCT03392168 · Phase 1/2 · registry result, not featured evidence
—0.15%
NCT03392168 · Phase 1/2 · registry result, not featured evidence
—0.5%
NCT03392168 · Phase 1/2 · registry result, not featured evidence
Serious AEs
0.7%0.3% creama
NCT04211363 · Phase 3
show 10 more results
0%0.3% cream
NCT04211389 · Phase 3
0%0.3% daily
NCT04746911 · Phase 2 · registry result, not featured evidence
0%0.3% cream
NCT04655313 · Phase 2 · registry result, not featured evidence
3.5%Cohort 1: Study 201 Participants
NCT03764475 · Phase 2 · registry result, not featured evidence
2%Cohort 2: Non-study 201 Participan
NCT03764475 · Phase 2 · registry result, not featured evidence
0.9%0.15%
NCT03638258 · Phase 2 · registry result, not featured evidence
0.9%0.3%
NCT03638258 · Phase 2 · registry result, not featured evidence
0%0.5%
NCT03392168 · Phase 1/2 · registry result, not featured evidence
0%0.15%
NCT03392168 · Phase 1/2 · registry result, not featured evidence
0%0.5%
NCT03392168 · Phase 1/2 · registry result, not featured evidence
Most frequent reported AEs
0.3% dailya
headache 10%
NCT04746911 · Phase 2 · registry result, not featured evidence
show 8 more results
0.3% cream
application site pain 5%
back pain 5%
candida infection 5%
NCT04655313 · Phase 2 · registry result, not featured evidence
upper respiratory tract infection 6.5%
NCT03764475 · Phase 2 · registry result, not featured evidence
upper respiratory tract infection 6.9%
NCT03764475 · Phase 2 · registry result, not featured evidence
0.15%
upper respiratory tract infection 6.4% (placebo 0%)
NCT03638258 · Phase 2 · registry result, not featured evidence
0.3%
upper respiratory tract infection 7.3% (placebo 0%)
NCT03638258 · Phase 2 · registry result, not featured evidence
0.5%
candiduria 12.5% (placebo 0%)
application site erythema 0% (placebo 12.9%)
application site pain 0% (placebo 16.1%)
NCT03392168 · Phase 1/2 · registry result, not featured evidence
0.15%
nasopharyngitis 7.1% (placebo 0%)
application site erythema 3.6% (placebo 12.9%)
application site pain 3.6% (placebo 16.1%)
NCT03392168 · Phase 1/2 · registry result, not featured evidence
0.5%
application site erythema 13.3% (placebo 12.9%)
application site pain 6.7% (placebo 16.1%)
nasopharyngitis 6.7% (placebo 0%)
NCT03392168 · Phase 1/2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Roflumilast (Zoryve)

IGA 0/1 42.4% (n=255) vs 6.1% (n=132) placebo @ 8wk0.3% cream
responder rate · % of participants
NCT04211363 · Phase 3 · converted to % from 108 Participants as posted
show 1 more result
37.5% (n=264) vs 6.9% (n=131) placebo @ 8wk*0.3% cream
NCT04211389 · Phase 3 · converted to % from 99 Participants as posted
Time to PASI-50 1.02 vs 3.42 placebo months0.3% cream
time to event · months
NCT04211363 · Phase 3 · converted to months from 31 days as posted
show 1 more result
0.99 vs NA placebo months*0.3% cream
NCT04211389 · Phase 3 · converted to months from 30 days as posted
PASI 75 41.6% (n=255) vs 7.6% (n=132) placebo @ 8wk0.3% cream
responder rate · % of participants
NCT04211363 · Phase 3 · converted to % from 106 Participants as posted
show 9 more results
39% (n=264) vs 5.3% (n=131) placebo @ 8wk*0.3% cream
NCT04211389 · Phase 3 · converted to % from 103 Participants as posted
13.3% (n=109) vs 10.5% (n=109) placebo @ 4wk0.3%
NCT03638258 · Phase 2 · registry result, not featured evidence
7.6% (n=113) vs 10.5% (n=109) placebo @ 4wk0.15%
NCT03638258 · Phase 2 · registry result, not featured evidence
24.1% (n=109) vs 9.6% (n=109) placebo @ 6wk0.3%
NCT03638258 · Phase 2 · registry result, not featured evidence
22.2% (n=113) vs 9.6% (n=109) placebo @ 6wk0.15%
NCT03638258 · Phase 2 · registry result, not featured evidence
31.3% (n=109) vs 13.2% (n=109) placebo @ 8wk0.3%
NCT03638258 · Phase 2 · registry result, not featured evidence
23% (n=113) vs 13.2% (n=109) placebo @ 8wk0.15%
NCT03638258 · Phase 2 · registry result, not featured evidence
34.1% (n=109) vs 16% (n=109) placebo @ 12wk0.3%
NCT03638258 · Phase 2 · registry result, not featured evidence
31.1% (n=113) vs 16% (n=109) placebo @ 12wk0.15%
NCT03638258 · Phase 2 · registry result, not featured evidence
PASI 90 22.4% (n=255) vs 2.3% (n=132) placebo @ 8wk0.3% cream
responder rate · % of participants
NCT04211363 · Phase 3 · converted to % from 57 Participants as posted
show 9 more results
15.5% (n=290) vs 2% (n=152) placebo @ 8wk*0.3% cream
NCT04211389 · Phase 3 · converted to % from 45 Participants as posted
6% (n=109) vs 2.3% (n=109) placebo @ 4wk0.3%
NCT03638258 · Phase 2 · registry result, not featured evidence
1.3% (n=113) vs 2.3% (n=109) placebo @ 4wk0.15%
NCT03638258 · Phase 2 · registry result, not featured evidence
14.3% (n=109) vs 3.2% (n=109) placebo @ 6wk0.3%
NCT03638258 · Phase 2 · registry result, not featured evidence
2.3% (n=113) vs 3.2% (n=109) placebo @ 6wk0.15%
NCT03638258 · Phase 2 · registry result, not featured evidence
16.9% (n=109) vs 6% (n=109) placebo @ 8wk0.3%
NCT03638258 · Phase 2 · registry result, not featured evidence
7.4% (n=113) vs 6% (n=109) placebo @ 8wk0.15%
NCT03638258 · Phase 2 · registry result, not featured evidence
20.6% (n=109) vs 7.8% (n=109) placebo @ 12wk0.3%
NCT03638258 · Phase 2 · registry result, not featured evidence
13.7% (n=113) vs 7.8% (n=109) placebo @ 12wk0.15%
NCT03638258 · Phase 2 · registry result, not featured evidence
I-IGA Clear or Almost Clear 71.2% (n=52) vs 13.8% (n=29) placebo @ 8wk0.3% cream
event count · % of participants
NCT04211363 · Phase 3 · converted to % from 37 Participants as posted
show 1 more result
68.1% (n=47) vs 18.5% (n=27) placebo @ 8wk*0.3% cream
NCT04211389 · Phase 3 · converted to % from 32 Participants as posted
IGA 0 63.5% (n=52) vs 10.3% (n=29) placebo @ 8wk0.3% cream
event count · % of participants
NCT04211363 · Phase 3 · converted to % from 33 Participants as posted
WI-NRS 4-point Reduction 33.5% (n=218) vs 20.9% (n=115) placebo @ 2wk0.3% cream
event count · % of participants
NCT04211363 · Phase 3 · converted to % from 73 Participants as posted
show 2 more results
46.3% (n=218) vs 15.7% (n=115) placebo @ 4wk*0.3% cream
NCT04211363 · Phase 3 · converted to % from 101 Participants as posted
59.2% (n=218) vs 22.6% (n=115) placebo @ 8wk*0.3% cream
NCT04211363 · Phase 3 · converted to % from 129 Participants as posted
I-IGA 0 57.4% (n=47) vs 7.4% (n=27) placebo @ 8wk0.3% cream
event count · % of participants
NCT04211389 · Phase 3 · converted to % from 27 Participants as posted
WI-NRS 4 Improvement 41.9% (n=215) vs 21.1% (n=109) placebo @ 2wk0.3% cream
event count · % of participants
NCT04211389 · Phase 3 · converted to % from 90 Participants as posted
show 2 more results
55.8% (n=215) vs 21.1% (n=109) placebo @ 4wk*0.3% cream
NCT04211389 · Phase 3 · converted to % from 120 Participants as posted
66.5% (n=215) vs 33% (n=109) placebo @ 8wk*0.3% cream
NCT04211389 · Phase 3 · converted to % from 143 Participants as posted
PSD -42.7 vs -16.7 placebo score @ 4wk0.3% cream
absolute change · score
NCT04211389 · Phase 3
show 1 more result
-49.3 vs -22.8 placebo score @ 8wk0.3% cream
NCT04211389 · Phase 3
IGA Clear or 'Almost Clear 44% (n=209) @ 12wk
event count · % of participants
No placebo or comparator arm
NCT03764475 · Phase 2 · registry result, not featured evidence · converted to % from 92 Participants as posted
show 15 more results
49.5% (n=95) @ 12wk*
NCT03764475 · Phase 2 · registry result, not featured evidence · converted to % from 47 Participants as posted
37.8% (n=209) @ 24wk*
NCT03764475 · Phase 2 · registry result, not featured evidence · converted to % from 79 Participants as posted
35.8% (n=95) @ 24wk*
NCT03764475 · Phase 2 · registry result, not featured evidence · converted to % from 34 Participants as posted
32.5% (n=209) @ 36wk*
NCT03764475 · Phase 2 · registry result, not featured evidence · converted to % from 68 Participants as posted
37.9% (n=95) @ 36wk*
NCT03764475 · Phase 2 · registry result, not featured evidence · converted to % from 36 Participants as posted
32.5% (n=209) @ 52wk*
NCT03764475 · Phase 2 · registry result, not featured evidence · converted to % from 68 Participants as posted
41.1% (n=95) @ 52wk*
NCT03764475 · Phase 2 · registry result, not featured evidence · converted to % from 39 Participants as posted
28.9% (n=38) @ 12wk*
NCT03764475 · Phase 2 · registry result, not featured evidence · converted to % from 11 Participants as posted
57.7% (n=26) @ 12wk*
NCT03764475 · Phase 2 · registry result, not featured evidence · converted to % from 15 Participants as posted
34.2% (n=38) @ 24wk*
NCT03764475 · Phase 2 · registry result, not featured evidence · converted to % from 13 Participants as posted
53.8% (n=26) @ 24wk*
NCT03764475 · Phase 2 · registry result, not featured evidence · converted to % from 14 Participants as posted
34.2% (n=38) @ 36wk*
NCT03764475 · Phase 2 · registry result, not featured evidence · converted to % from 13 Participants as posted
38.5% (n=26) @ 36wk*
NCT03764475 · Phase 2 · registry result, not featured evidence · converted to % from 10 Participants as posted
23.7% (n=38) @ 52wk*
NCT03764475 · Phase 2 · registry result, not featured evidence · converted to % from 9 Participants as posted
38.5% (n=26) @ 52wk*
NCT03764475 · Phase 2 · registry result, not featured evidence · converted to % from 10 Participants as posted
Duration of Response 1.85 months
time to event · months
No placebo or comparator arm
NCT03764475 · Phase 2 · registry result, not featured evidence · converted to months from 8 weeks as posted
show 1 more result
2.86 months*
NCT03764475 · Phase 2 · registry result, not featured evidence · converted to months from 12.4 weeks as posted

+ 10 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Mufemilast's landscape · Roflumilast (Zoryve)'s landscape